Pacira BioSciences appoints Laura Brege as Board Chair; two directors retire

Pacira BioSciences, Inc.

Paul J. Hastings (former Chair) and Andreas Wicki retired effective Jan. 28, 2025; no disagreement cited.
Laura Brege appointed Chair; brings 30 years pharma/biotech executive experience.
Board reduced from 12 to 9 directors; 8 of 9 are independent; 5 joined since Oct. 2023.
Alethia Young succeeds Brege as Audit Committee Chair; other committee assignments refreshed.
Brege previously held leadership roles at BridgeBio, Onyx Pharmaceuticals, and COR Therapeutics.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Paul J. Hastings

Chair of the Board

PCRX · Pacira BioSciences, Inc.

Effective: 2025-01-28
Successor: Laura Brege
Filed: January 30, 2025, 6:59 PM ET

On January 28, 2025, Paul J. Hastings, Chair of the Board of Directors (the “Board”), and Andreas Wicki, a member of the Board, each notified the Board of Pacira BioSciences, Inc. (the “Company”) of his respective decision to resign as a member of the Board, in each case, effective immediately

Departed

Andreas Wicki

Member of the Board

PCRX · Pacira BioSciences, Inc.

Effective: 2025-01-28
Filed: January 30, 2025, 6:59 PM ET

On January 28, 2025, Paul J. Hastings, Chair of the Board of Directors (the “Board”), and Andreas Wicki, a member of the Board, each notified the Board of Pacira BioSciences, Inc. (the “Company”) of his respective decision to resign as a member of the Board, in each case, effective immediately

Appointed

Laura Brege

Chair of the Board

PCRX · Pacira BioSciences, Inc.

Effective: 2025-01-28
Filed: January 30, 2025, 6:59 PM ET

the Board, upon recommendation of the Nominating, Governance and Sustainability Committee of the Board, appointed Laura Brege as Chair of the Board, effective as of immediately following the effectiveness of the Resignations.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Paul J. Hastings resigned as Chair of the Board at Pacira BioSciences, Inc..

Action: resigned
Role: Chair of the Board

Exact text from the filing

On January 28, 2025, Paul J. Hastings, Chair of the Board of Directors (the “Board”), and Andreas Wicki, a member of the Board, each notified the Board of Pacira BioSciences, Inc. (the “Company”) of his respective decision to resign as a member of the Board, in each case, effective immediately

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Andreas Wicki resigned as Member of the Board at Pacira BioSciences, Inc..

Action: resigned
Role: Member of the Board

Exact text from the filing

On January 28, 2025, Paul J. Hastings, Chair of the Board of Directors (the “Board”), and Andreas Wicki, a member of the Board, each notified the Board of Pacira BioSciences, Inc. (the “Company”) of his respective decision to resign as a member of the Board, in each case, effective immediately

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Laura Brege was appointed as Chair of the Board at Pacira BioSciences, Inc..

Action: appointed
Role: Chair of the Board

Exact text from the filing

the Board, upon recommendation of the Nominating, Governance and Sustainability Committee of the Board, appointed Laura Brege as Chair of the Board, effective as of immediately following the effectiveness of the Resignations.

View on SEC.gov

Pacira BioSciences, Inc. filing history →

Source: SEC EDGAR

accession 0001396814-25-000022

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.